Montana State University researchers have identified a biological pathway that allows cells to produce the essential amino acid cysteine when primary systems fail, a process previously deemed impossible by the scientific community. Published May 21 in Nature Chemical Biology, the discovery reveals how mammalian cells utilize a backup mechanism to cleave carbon-sulfur bonds in cystine, potentially offering a new target for cancer therapies that rely on similar survival pathways.
How Do Cells Survive Without Traditional Reductase Systems?
For decades, biological consensus held that all cells required a functioning disulfide reductase system to convert cystine into cysteine, an amino acid vital for protein structure and cellular defense. According to lead author Ed Schmidt, a professor of genetics and development at Montana State University, the research team identified a secondary pathway that bypasses the need for traditional reductases. When primary systems are disabled, cells chemically sever an adjacent carbon-sulfur bond in cystine to isolate the cysteine they require for survival. This mechanism was observed in genetically engineered mice that lacked the standard disulfide reductase enzymes in their livers, yet remained viable.
The discovery of this backup pathway took nine years of research, beginning with an unexpected “aha moment” in 2014 when laboratory mice survived conditions that were, according to established science, considered lethal.
Why Does This Discovery Matter for Cancer Treatment?
The newly identified cellular defense system may explain how cancer cells withstand aggressive medical interventions, including chemotherapy, radiation, and immunotherapy. Schmidt notes that the pathway likely evolved in ancient multicellular organisms as a defense against environmental electrophilic toxins. Because cancer cells often hijack existing survival mechanisms to resist treatment, disabling this specific backup pathway could theoretically render tumors significantly more vulnerable to standard therapies. By targeting this chemical process, researchers aim to develop precision treatments that strip cancer cells of their ability to maintain protein stability under stress.

The Evolution of Cellular Defense
The ability to persist without a disulfide reductase system is not a modern mutation, but rather an evolutionary safeguard. Research suggests this mechanism allowed early multicellular ancestors to consume organisms that produced harmful toxins. By maintaining an alternative route to produce cysteine, these organisms could neutralize threats that would otherwise kill them. According to the study, this ancient survival trait is now a focal point for understanding how modern human cells—and malignant tumors—manage to survive in hostile environments.

Collaborative Research Efforts
The breakthrough was achieved through a multi-year partnership between Montana State University and the Hungarian National Institute of Oncology. Peter Nagy, a collaborator from the Budapest-based institute, provided the specialized analytical capabilities necessary to map the chemical process. The research team also included several undergraduate and doctoral students, such as co-first authors Zoe Seaford and Sydney Austad, who contributed to the laboratory experiments over the course of the study.

Frequently Asked Questions
- What is cysteine and why do cells need it? Cysteine is an amino acid essential for building proteins and forming disulfide bonds, which provide cells with their necessary three-dimensional structure.
- Why was this discovery considered impossible? Scientists previously believed that the disulfide reductase system was the only way for cells to access cysteine, as the amino acid is not available externally.
- How could this lead to cancer treatment? If cancer cells use this backup system to survive chemotherapy or radiation, developing drugs to block this pathway could make tumors easier to eradicate.
Follow the latest publications in Nature Chemical Biology to track how this fundamental research progresses from cellular discovery to potential clinical trials.
Have questions about how this genetic research might impact future medicine? Join the conversation in the comments section below or subscribe to our research newsletter for updates on this study.













